Company intelligence / Profile preview
VGI Health Technology
Lane Cove, New South Wales, Australiavgiht.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
VGI Health Technology has reached Phase 2 clinical trials in pancreatic cancer and non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH), with ethics approval granted for human trials. Its MELT3 nutraceuticals are ready for US commercial launch; clinical efficacy results have not yet been published in peer-reviewed format, but the company has reported successful trial initiation and human dosing for lead programs.[1][2][5][3][4][6][7]
- Therapeutic areas
- CardiovascularEndocrinologyRheumatologyGastroenterologyOtherOncology
- Modalities
- Small moleculeNutraceutical
- Industry
- Biotech
02
Drug pipeline
2 assets1 more asset in the full pipeline.
03
Partnerships
Hebei Visual Medical Technology Co. Ltd
Beyond the preview
Go deeper on VGI Health Technology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on VGI Health Technology.